Literature DB >> 17352682

Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.

Pieter Van der Veken1, Achiel Haemers, Koen Augustyns.   

Abstract

Dipeptidyl peptidase IV (DPP IV) is a validated target for the treatment of type 2 diabetes, with several inhibitors currently in phase 3 clinical trials. This review will mainly focus on proline-specific dipeptidyl peptidases related to DPP IV: fibroblast activation protein (FAP), dipeptidyl peptidase 8 (DPP8), dipeptidyl peptidase 9 (DPP9) and dipeptidyl peptidase II (DPP II). The biochemical and biological properties of these enzymes will be discussed, as well as the therapeutic potential of their inhibition. The development of potent and selective inhibitors for each of these peptidases will be described.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17352682     DOI： 10.2174/156802607780091046

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN： 1568-0266            Impact factor:   3.295


  11 in total

1.  Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions.

Authors:  Yan Huang; Avis E Simms; Anna Mazur; Sophie Wang; Noel R León; Barry Jones; Nazneen Aziz; Thomas Kelly
Journal:  Clin Exp Metastasis       Date:  2011-05-22       Impact factor: 5.150

2.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Authors:  Koen Jansen; Leen Heirbaut; Jonathan D Cheng; Jurgen Joossens; Oxana Ryabtsova; Paul Cos; Louis Maes; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2013-03-18       Impact factor: 4.345

3.  Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors.

Authors:  Katarzyna Kaczanowska; Karl-Heinz Wiesmüller; Arnaud-Pierre Schaffner
Journal:  ACS Med Chem Lett       Date:  2010-10-05       Impact factor: 4.345

4.  The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides.

Authors:  Ruth Geiss-Friedlander; Nicolas Parmentier; Ulrike Möller; Henning Urlaub; Benoit J Van den Eynde; Frauke Melchior
Journal:  J Biol Chem       Date:  2009-08-10       Impact factor: 5.157

5.  Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.

Authors:  Véronique Dubois; Chris Van Ginneken; Hilde De Cock; Anne-Marie Lambeir; Pieter Van der Veken; Koen Augustyns; Xin Chen; Simon Scharpé; Ingrid De Meester
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

6.  Rhinorrhea, cough and fatigue in patients taking sitagliptin.

Authors:  James N Baraniuk; Mary J Jamieson
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-12       Impact factor: 3.406

7.  Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.

Authors:  Arumugam Kodimuthali; Padala Lakshmi Prasunamba; Manojit Pal
Journal:  Beilstein J Org Chem       Date:  2010-07-01       Impact factor: 2.883

Review 8.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

9.  Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.

Authors:  Jay Shubrook; Randall Colucci; Aili Guo; Frank Schwartz
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2011-01-12

10.  Asymmetric synthesis of γ-chloro-α,β-diamino- and β,γ-aziridino-α-aminoacylpyrrolidines and -piperidines via stereoselective Mannich-type additions of N-(diphenylmethylene)glycinamides across α-chloro-N-sulfinylimines.

Authors:  Gert Callebaut; Sven Mangelinckx; Pieter Van der Veken; Karl W Törnroos; Koen Augustyns; Norbert De Kimpe
Journal:  Beilstein J Org Chem       Date:  2012-12-05       Impact factor: 2.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.